Trial intelligence / Profile preview

Intranasal Insulin for Cognition in T2DM

NCT01206322Phase 2Completed

Sponsor
Beth Israel Deaconess Medical Center
Start
May 2010
Primary completion
Apr 2013
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of regular human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Brief Visuospatial Spatial Memory Test - Total Recall at 2 hours and Right Insular Cortex Perfusion at 2 hours. Started May 2010; status: completed.

02

Drugs

regular human insulin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01206322.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01206322.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call